Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2000

View Archived Issues

Cerus continues phase III trial of platelet pathogen inactivation system in Europe

Two additional U.S. patents allowed for Maxamine technology

NPS Allelix drug candidate enhances bone growth in space shuttle experiments

Arena and Fujisawa establish collaboration in neurodegenerative disease area

Cambridge Drug Discovery and Parke-Davis complete screening collaboration

IND filed for nasal leuprolide as endometriosis therapy

Telik initiates clinical testing of first development candidate

Novel agent for treatment-refractory CIS now under review in Canada

Idun and Elan establish stroke therapy collaboration

Novel isatin derivatives with broad-spectrum antibacterial and antifungal activity

Alexion to commence development of 5G1.1 for treatment of dermatomyositis

Elan establishes new agreement with Wyeth-Ayerst for integrin inhibitors

Combidex contrast agent receives priority review status from FDA

Focus on carbapenem modifications continues at Merck

Emtricitabine-containing HAART regimen is highly efficacious in French study

Potent, broad-spectrum cephalosporins in development at Roche

Preliminary results in volunteers reinforce the promise of DuPont's second-generation NNRTIs

Incyte patents novel GFMOs for cancer and fibrotic disorders

Boston Life Sciences identifies target of CNS growth factor products

Novel 5-HT7 antagonists for CNS disorders under investigation at DuPont

Lilly describes 5-HT1F agonists as potential antimigraine agents

Aventis Behring launched

Lilly assesses potential utility of PLA2 inhibitors for septic shock

Roxane launches orphan drug for treatment of apnea in premature infants

BMS informs of first launch for new quinolone

Pliva presents new azithromycin derivatives at ICMASKO 5

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...